June 23, 2020 C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19 Clinicians to report novel uses of existing drugs through FDA-NCATS CURE ID Mobile App. TUCSON, Ariz., June 23, 2020 — As millio
June 20, 2020 C-Path’s Transplant Therapeutics Consortium Receives Acceptance of Letter of Intent for iBox Scoring System (Composite Biomarker Panel) as a Reasonably Likely Surrogate Endpoint Biomarker aims to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplan
June 19, 2020 Method of Blood Pressure Measurement in Neonates and Infants: A Systematic Review and Analysis
June 14, 2020 Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington’s Disease
June 12, 2020-June 18, 2020 The Rare Disease Clinical Outcome Assessment Consortium: Aiming to Fulfill Unmet Drug Development Endpoint Measurement Needs Presented at the DIA Virtual Global Annual Meeting, held June 12 – 18, 2020.
June 11, 2020 From the Regulatory Affairs Professional Society (RAPS): FDA’s CURE ID app gets a COVID-19 refresh An online case reporting platform has been optimized for COVID-19 and will be the springboard for a new public-private drug
June 5, 2020 Watch now: What You Need to Know About the Rare Disease Cures Accelerator-Data and Analytics Platform Webinar Join C-Path, the National Organization for Rare Disorders and the FDA for a free 1-hour webinar on the Rare Disease Cures Accelera
May 14, 2020 Serum Glutamate Dehydrogenase Activity Enables Early Detection of Liver Injury in Subjects with Underlying Muscle Impairments
May 13, 2020 C-Path and Provention Bio Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes TUCSON, Ariz., and OLDWICK, N.J. May 13, 2020 — The Critical Path Institute (C-Path) and Provention Bio, Inc. (Nas
